271 related articles for article (PubMed ID: 20151157)
1. New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.
Cannata-Andía JB; Rodriguez-García M; Román-García P; Tuñón-le Poultel D; López-Hernández F; Rodríguez-Puyol D
Pediatr Nephrol; 2010 Apr; 25(4):609-16. PubMed ID: 20151157
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
3. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
4. Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Cozzolino M; Galassi A; Pasho S; Fallabrino G; Gallieni M; Brancaccio D
Contrib Nephrol; 2008; 161():234-239. PubMed ID: 18451682
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
Akiba T
Clin Calcium; 2007 May; 17(5):767-71. PubMed ID: 17471008
[TBL] [Abstract][Full Text] [Related]
8. [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
Sułowicz W
Przegl Lek; 2006; 63 Suppl 3():3-9. PubMed ID: 16898475
[TBL] [Abstract][Full Text] [Related]
9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
10. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
11. New approaches to treatment of secondary hyperparathyroidism.
Locatelli F; Limardo M; Pontoriero G
Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
[TBL] [Abstract][Full Text] [Related]
12. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
13. New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.
Brancaccio D; Cozzolino M; Pasho S; Fallabrino G; Olivi L; Gallieni M
Contrib Nephrol; 2009; 163():219-226. PubMed ID: 19494617
[TBL] [Abstract][Full Text] [Related]
14. Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients.
Kumar J; Tran NT; Schomberg J; Streja E; Kalantar-Zadeh K; Pahl M
J Ren Nutr; 2016 Jul; 26(4):265-9. PubMed ID: 27038806
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Quarles LD
Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
[TBL] [Abstract][Full Text] [Related]
16. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
17. Calcimimetics versus vitamin D: what are their relative roles?
Drüeke TB
Blood Purif; 2004; 22(1):38-43. PubMed ID: 14732810
[TBL] [Abstract][Full Text] [Related]
18. Impact of non-traditional phosphate binders and cinacalcet on haemodialysis patient biochemistry, pill burden and cost.
Gray NA; Krishnasamy R; Vardesh DL; Hollett PR; Anstey CM
Nephrology (Carlton); 2011 Nov; 16(8):688-96. PubMed ID: 21649793
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
20. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]